Philippines aims to expedite IP violation cases with Rapid Rules

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Philippines aims to expedite IP violation cases with Rapid Rules

Sponsored by

hechanova-400px.png
flag-1195392.jpg

As the Intellectual Property Office of the Philippines invites public comments on a proposal to streamline the adjudication of intellectual property violation cases, Editha R Hechanova of Hechanova Group summarises the key measures

In a move to expedite the resolution of intellectual property (IP) violation cases, on June 25 2024 the Intellectual Property Office of the Philippines opened a public consultation on its proposed Rules of Procedure on Resolution of Actions without Provisional Remedies in IP Cases with Delimited Damages (the Rapid Rules). The deadline for the submission of comments is July 25 2024.

The salient points of the Rapid Rules are as follows:

  • The rules apply only to IP cases in which no provisional remedies are prayed for.

  • The damages claimed, including attorney’s fees and other legal costs, should not be lower than PHP 200,000 but should not exceed PHP 500,000.

  • No motion to dismiss on any of the grounds mentioned in the Rules of Court or in any other law shall be allowed, except on the ground of prescription.

  • By agreement of the parties, hearings may be conducted via online videoconference, by filing a joint motion at least seven days before the scheduled hearing.

  • Affidavits of witnesses shall be prepared in the language known to them, with an English translation if not in English, and shall contain, among others, a statement that they are answering the questions under oath and are fully conscious that they may face criminal liability for false testimony or perjury.

  • Complaints filed under the Rapid Rules must be verified and filed within four years from the date of commission of the violation, or if the date is unknown, from the date of discovery of the violation. The filing of the verified complaint and other submissions shall be by email and failure to comply shall be a ground for dismissal of the complaint.

  • Substantial evidence shall be sufficient to support a decision or an order.

  • Trials are expedited, with the hearing officer setting the case for successive and continuous trial, and the parties are given five days each to present their evidence. The decision of the hearing office shall be issued within 60 calendar days after the case is submitted for resolution.

  • The director or hearing officer is not bound by the technical rules of evidence, shall receive relevant and material evidence, and shall act according to justice and fairness.

more from across site and SHARED ros bottom lb

More from across our site

The Texas-based IP litigation hires take King & Spalding’s partner appointments from pre-merger Winston & Strawn up to 12 this year
Sunny Su explains how her team overcame challenges with orchard evidence collection to secure a favourable plant variety decision from China’s top court
Flexible working firm continues trajectory from 2025 with appointment of Matthew Grant and Letao Qin
Anousha Davies, associate and trademark attorney at Birketts, unpicks how the university’s reputation enabled it to see off a proposed trademark for ‘Cambridge Rowing’
IP lawyers, who say they are encouraging clients to build up ‘tariff resilience’, should treat the risks posed by recent orders as a core consideration in cross-border licensing
Regulatory changes and damages risks are prompting Canadian firms and clients to opt for settlements in generic and biosimilar cases
News of Via Licensing Alliance adding two new members and Nokia’s proposal to extend interim licences to Warner Bros Discovery and Paramount were also among the top talking points
A new claim filed by Ericsson, and a request for access to documents, were also among recent developments
Cooley and Stikeman Elliott advised 35Pharma on the deal, which will allow GSK to get its hands on S235, an investigational medicine for pulmonary hypertension
Simon Wright explains why the UK should embrace the possibility of rejoining the UPC, and reveals how CIPA is reacting to this month’s historic Emotional Perception AI case at the UK Supreme Court
Gift this article